Incyte Corporation[Grants and Funding] - Search Results

Year	Number of Results
2018	3
2019	5
2020	5
2021	3
2022	9
2023	8
2024	7

1

The future of immunotherapy for diffuse large B-cell lymphoma.

Duell J, Westin J. Duell J, et al. Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35156. Online ahead of print. Int J Cancer. 2024. PMID: 39319495 Review.

2

Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort.

Ezzedine K, Seneschal J, Da Silva A, Préaubert N, Lamblin A, Delattre C, Emery C, Nevoret C, Finzi J, Bouée S, Passeron T. Ezzedine K, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2249-2258. doi: 10.1111/jdv.19447. Epub 2023 Aug 31. J Eur Acad Dermatol Venereol. 2023. PMID: 37605309

3

Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks.

Passeron T, Harris JE, Pandya AG, Seneschal J, Grimes P, Kornacki D, Wang M, Ezzedine K, Rosmarin D. Passeron T, et al. J Eur Acad Dermatol Venereol. 2024 Jul 16. doi: 10.1111/jdv.20236. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39011655 No abstract available.

4

The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes.

Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. Picardo M, et al. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1507-1523. doi: 10.1111/jdv.18129. Epub 2022 May 11. J Eur Acad Dermatol Venereol. 2022. PMID: 35366355 Free PMC article. Review.

5

Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.

Simpson EL, Kircik L, Blauvelt A, Kallender H, Kuo Y, Ren H, Sturm D, Eichenfield LF. Simpson EL, et al. J Dermatol. 2023 Dec;50(12):1523-1530. doi: 10.1111/1346-8138.16975. Epub 2023 Oct 13. J Dermatol. 2023. PMID: 37830436 Clinical Trial.

6

Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.

Liu H, Santos LL, Smith SH. Liu H, et al. Int J Mol Sci. 2023 Apr 13;24(8):7185. doi: 10.3390/ijms24087185. Int J Mol Sci. 2023. PMID: 37108348 Free PMC article. Clinical Trial.

7

Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study.

Hamzavi IH, Bibeau K, Grimes P, Harris JE, van Geel N, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Ren H, Ezzedine K. Hamzavi IH, et al. Br J Dermatol. 2023 Oct 25;189(5):569-577. doi: 10.1093/bjd/ljad245. Br J Dermatol. 2023. PMID: 37493275

8

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.

Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Hamadani M, et al. Hematol Oncol. 2023 Dec;41(5):848-857. doi: 10.1002/hon.3209. Epub 2023 Jul 26. Hematol Oncol. 2023. PMID: 37496298 Clinical Trial.

9

Evaluation of drug-drug interactions of pemigatinib in healthy participants.

Ji T, Rockich K, Epstein N, Overholt H, Wang P, Chen X, Punwani N, Yeleswaram S. Ji T, et al. Eur J Clin Pharmacol. 2021 Dec;77(12):1887-1897. doi: 10.1007/s00228-021-03184-z. Epub 2021 Jul 19. Eur J Clin Pharmacol. 2021. PMID: 34282472

10

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).

Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K; BREEZE-AD4 study group. Bieber T, et al. Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year